Benitec Biopharma Inc. reports 100% responder rates for BB-301 with a mid-2026 FDA meeting ahead. See why BNTC stock is upgraded to buy.

Skyhawk Therapeutics announces interim results in patients from phase 1 clinical trial as a treatment for Huntington’s disease: Waltham, Massachusetts Thursday, January 29, 2026 ...

QIAsprint Connect marks entry into high-throughput sample processing, enabling labs to scale workflows with flexible ...

Your surroundings may influence your social behavior more than you realize. New research from the Brain Research Institute at ...

Farming animals for fur is not only cruel but also provides an ideal environment for viruses to mix and cross over into ...

Artificial intelligence (AI) is now an essential tool in biopharma manufacturing, yet industry still needs guidelines on how LLMs, ML, and other technologies should be used in drug making, say the ...

Mainland China's issuers will still dominate city's IPO market, executive says, but US and Southeast Asian companies are also ...

Antal and Yeo, who also are members of UCSD’s Moores Cancer Center, say the key to targeting triple-negative breast cancer, or TNBC, is managing a protein called poly (U)-binding splicing factor 60, ...

Non-specific Endonuclease Market to reach US$ 726.6 Bn by 2036 at 6.5% CAGR, driven by rising biotechnology research, ...

Continuous monitoring of biomarkers is essential for early disease detection, treatment evaluation, and personalized health ...

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced another major independent validation of its AI and machine learning (ML) capabilities in a ...